TrialEuropean journal of neurology2024

Time to response with ravulizumab, a long-acting terminal complement inhibitor, in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis.

Ali A Habib et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.